HGSOC Clinical Trials

6 recruitingLast updated: June 26, 2026

There are 6 actively recruiting hgsoc clinical trials across 12 countries. Studies span Phase 1, Phase 2, Not Applicable, Phase 3. Top locations include London, United Kingdom, Houston, Texas, United States, Basel, Canton of Basel-City, Switzerland. Updated daily from ClinicalTrials.gov.


HGSOC Trials at a Glance

6 actively recruiting trials for hgsoc are listed on ClinicalTrialsFinder across 6 cities in 12 countries. The largest study group is Phase 1 with 4 trials, with the heaviest enrollment activity in London, Houston, and Basel. Lead sponsors running hgsoc studies include Swiss GO Trial Group, AstraZeneca, and Bristol-Myers Squibb.

Browse hgsoc trials by phase

Treatments under study

About HGSOC Clinical Trials

Looking for clinical trials for HGSOC? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new HGSOC trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about HGSOC clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Phase 1Phase 2

A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors

ER+ HER2- Advanced Breast CancerHigh-grade Serous Ovarian Cancer (HGSOC)
AstraZeneca564 enrolled14 locationsNCT06188520
Recruiting
Phase 1

Study of CryptiVax-1001 in Maintenance Setting for Advanced Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian CancerHGSOCHGS Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Epitopea Ltd50 enrolled10 locationsNCT07665515
Recruiting
Not Applicable

OV Precision: Study Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy

High-grade Serous Ovarian Carcinoma (HGSOC)Fallopian Tube NeoplasmsOvarian Neoplasm Epithelial+1 more
Swiss GO Trial Group60 enrolled7 locationsNCT06466382
Recruiting
Phase 1Phase 2

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

Head and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)Triple Negative Breast Cancer(TNBC)+3 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.230 enrolled13 locationsNCT05985655
Recruiting
Phase 1

A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.

Non-small Cell Lung Cancer (NSCLC)High-grade Serous Ovarian Carcinoma (HGSOC)Uterine Serous Carcinoma (USC)
Bristol-Myers Squibb240 enrolled17 locationsNCT06476808
Recruiting
Phase 3

MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)

High-grade Serous Ovarian Carcinoma (HGSOC)Fallopian Tube NeoplasmsOvarian Neoplasm Epithelial+3 more
Swiss GO Trial Group540 enrolled53 locationsNCT04111978